HomeTOP STORIESAcad projects $244.3M Q1 revenue with DAYBUE and NUPLAZID growth, anticipates accelerated... Acad projects $244.3M Q1 revenue with DAYBUE and NUPLAZID growth, anticipates accelerated Prader-Willi trial data By rogerjudd May 8, 2025 FacebookTwitterPinterestWhatsApp Post Content Previous articleInogen targets $352M-$355M in 2025 revenue with focus on B2B growth and strategic innovationsNext articleRookie Philadelphia police officer shot in stomach while trying to break up fight near high school latest articles The inflation process has shifted even as headline CPI declined – Federal Reserve Cerrado Gold reports Q4 results As H-1B Visa Program Changes, Skilled Foreign Workers Consider Leaving U.S. They Get Drunk Without Drinking: What It’s Like to Have Auto-brewery Syndrome Parents Who Borrowed for Children’s College Face Looming Deadline Watch: Artemis II’s journey so far… in 85 seconds explore more The inflation process has shifted even as headline CPI declined – Federal Reserve Cerrado Gold reports Q4 results As H-1B Visa Program Changes, Skilled Foreign Workers Consider Leaving U.S. They Get Drunk Without Drinking: What It’s Like to Have Auto-brewery Syndrome Parents Who Borrowed for Children’s College Face Looming Deadline Watch: Artemis II’s journey so far… in 85 seconds
